Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial.

MLA

Rashidi, Farid, et al. “Tissue Plasminogen Activator for the Treatment of Adults with Critical COVID-19: A Pilot Randomized Clinical Trial.” Thrombosis Research, vol. 216, Aug. 2022, pp. 125–28. EBSCOhost, https://doi.org/10.1016/j.thromres.2021.12.003.

APA

Rashidi, F., Barco, S., Rezaeifar, P., Sadeghipour, P., Ghodrati, S., Bakhshandeh, H., Mousavi-Aghdas, S. A., Sadeghi, A., Sharifi, A., Valizadeh, H., Mikaeili, H., Rafiee, F., Navarbaf, Z., Farajian, G., Mahmoodpoor, A., Bikdeli, B., & Ansarin, K. (2022). Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial. Thrombosis Research, 216, 125–128. https://doi.org/10.1016/j.thromres.2021.12.003

Chicago

Rashidi, Farid, Stefano Barco, Parisa Rezaeifar, Parham Sadeghipour, Samad Ghodrati, Hooman Bakhshandeh, Seyed Ali Mousavi-Aghdas, et al. 2022. “Tissue Plasminogen Activator for the Treatment of Adults with Critical COVID-19: A Pilot Randomized Clinical Trial.” Thrombosis Research 216 (August): 125–28. doi:10.1016/j.thromres.2021.12.003.